Status:

COMPLETED

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Lead Sponsor:

AstraZeneca

Conditions:

Obesity

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Subject has completed Protocol 137OB-201.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2007

    Estimated Enrollment :

    210 Patients enrolled

    Trial Details

    Trial ID

    NCT00189514

    Start Date

    September 1 2005

    End Date

    June 1 2007

    Last Update

    June 11 2015

    Active Locations (21)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 6 (21 locations)

    1

    Research Site

    Chula Vista, California, United States

    2

    Research Site

    San Diego, California, United States

    3

    Research Site

    Walnut Creek, California, United States

    4

    Research Site

    Miami, Florida, United States